• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Cytovance Biologics

    Adare Pharma Solutions

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    PCI Pharma Services

    Alcami

    Baxter BioPharma Solutions

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Finding the “Missing Link”

    Outsourcing and the supply chain

    Finding the “Missing Link”
    Emil W. Ciurczak, DoraMaxx Consulting10.11.17
    “If you love something, let it go.” This is the wisdom of our elders and advice column writers. In manufacturing, producing almost any “widget” (cars, planes, moon rockets, TVs, etc.), it has long been the practice to use sub-contractors to produce the smaller pieces and the “mother plant” assemble and distribute the finished goods. I remember John Glenn being asked what he was thinking while waiting for lift-off. He answered, “I was sitting on a million pounds of explosive fuel, in a ship made from a million components, each supplied by the lowest bidder.”

    The emerging paradigm for pharmaceutical manufacturing is to have more and more of the “pieces” of the final product fabricated off-campus. In the “good old days” (1950s-80s), the excipients were, of course, bought from a supplier. Can you imagine a major pharma company with a farm, where they harvest milk for lactose or grains for starch? The difference between then and now is that we knew from whence came the materials. Talc was a product of Alabama, cornstarch was from our mid-west, most APIs were made in-house or by a nearby contractor, etc.

    We still purchase these excipients and APIs, but now, we are called upon to trust other Agencies, other than FDA, USDA, or EMA, in countries where the agencies seldom have the personnel, force of law, or resources to monitor production processes—raw materials, intermediates, or finished products. In the past—1940s through the 1990s—the way in which we cleared these raw materials for use in our products was two-fold:
    1. We accepted certificates of analysis (CoA) and “spot-sampled” some containers of some, if not every, lot(s) for simple tests (ID by USP methods, visuals, organoleptic tests), or
    2. We took some samples (e.g., √N + 1, meaning 11 of over 100 containers tested) and performed a full monograph (USP, BP, EP) of tests.
    Anyone who has ever performed these tests knows they are meant to give an identity (often inferential) and general purity profile (heavy metals, sterility). Even the “quick and dirty” sieve analyses tests are merely meant to “confirm” the grade of material supplied. All testing is based on trust. That is, trust that the supplier:
    • Knows what the final product looks like (has experience supplying Pharma companies);
    • Has GMP training;
    • Has competent regulatory oversight; and
    • Actually cares about providing a quality product
    Back when I was considering the EMEA (as it was named then, EMA now) “suggestion” to qualify 100% of all containers of incoming raw materials for my NIR program, I found there was no “paper trail” for raw materials. This was before the Vendor Validation concept was initiated (and, betraying my age, even before cGMPs were in force). I designed a form wherein I determined the source of the material (mined, purified, or synthesized); what else originated at that source (possible mislabeling); was the product relabeled or repackaged and where by whom; and any other pertinent detail that would make or break the “chain of custody.” In other words, how much of the CoA was to be trusted?

    In 1984, with the supply chain only extended from the Atlantic to the Pacific and Canada to Mexico, this “due diligence” was sufficient. However, these were simpler times. In recent years, with the concept of global outsourcing of both raw materials and manufacturing (as well as R&D), these naïve checks cannot be counted upon to protect the supply chain/patients. As with any international treaty, we need to follow the “trust, but verify” doctrine. As a clear example, I refer to the heparin disaster of a few years back.

    To refresh any memories that need refreshing, heparin from China was contaminated (if 50% impure can be called contamination) with over-sulfated chondroitin (OSC). OSC is structurally is chemically similar to heparin, with the same pieces, merely in a different order. Taken orally, OSC is used for treating arthritis but, intravenously, it is toxic and killed a number of people before the cause was discovered. Why? Standard USP tests could not discriminate between the two materials. Why? Remember trust? There was never a need to tell the difference. The “usual suspects,” I mean, traditional suppliers would never substitute OSC for heparin, so we never needed to check for OSC before. Then there was the contamination of pet food with melamine, killing numerous animals. The “usual” tests could not determine its presence. Sadly, the USDA at U.S. ports tested for its presence in OUTGOING grains since 1980, but not for imports.

    Now, with a 15,000-mile supply chain, with hundreds, if not thousands, of inputs, we need an entirely different paradigm. We must find the most efficient, yet cost-effective methods of supply chain control. Happily, there is a “good news-bad news” convergence of needs here. Simultaneously, we find a need to ascertain the quality of an incoming material or (externally) finished product for safety and provenance (authenticity) and the need to know much of the same to be able to run a proper Quality by Design (QbD) program.

    Having already established that a compendial monograph is not, in any way, helpful as a source of data on whether or not a given material will aid or hinder a production run, it is also disconcerting to realize that it may also not be capable of determining false or out-of-specification (OOS) materials. If we take the USP monograph for lactose, for example, we can see the lack of specificity:
    1. Boil the material in a copper salt. If it turns red, confirm a reducing sugar.
    2. An ammonia solution has a specific optical rotatory value, which actually changes with time and yet there is no time component in the monograph.
    3. Particle size is “determined” by how much material is retained on, say, a 100-mesh screen. (No range, no accommodation for static clumping, no actual lower limit, even though micronized particles could pass the same test as 100-mesh material.)
    4. No polymorphic or crystallinity parameters.
    5. Yes, a mid-range IR is run, but, unless a sophisticated program is run (USP only specifies “looks like”), most sugars resemble one another.
    Now, it is in the interest of both safety and commercial quality that we have meaningful tests and the technologies to run them. That means “securing the supply chain” for incoming raw materials is determining the physical and chemical parameters (of course, those based on the critical process parameters, CPP, determined in the QbD program via an Design of Experiment, DoE). The simplest, and first test, is the identity of a raw material. Since we have a number of spectrometric tools at hand, this will be far more definitive than a simple compendial “identity” test. With NIRS or Raman. Running Chemometric algorithms, a single spectrum can determine the polymorphic form, degree of crystallinity, moisture level (surface vs. crystalline), and, with NIRS, average particle size.

    These data not only show adherence to incoming product specifications, which are, of course, a range, not a single value, but act as a fingerprint of a “quality” product. Coincidentally, this fingerprint occurs with properly made finished products. The “process signature” is what, in fact, is used by the controlling software to estimate the dissolution parameter, hardness, content uniformity, and so forth… the process signature is the “passing product signature.” Clearly, this is not just a way to pass a product, not just a way to show a quality product, but to show that it is properly made by a contract manufacturing organization (CMO).

    Since my first full-time position in Pharma in 1970 (yes, AD!) was to search for potential perform drug-packaging interactions, I learned:
    1. How important proper packaging can be for the protection and dispensing of products; and
    2. How to properly assay/qualify the packaging material.
    Overall, I personally believe that packaging is the “Cinderella” of the pharmaceutical supply chain. By that I mean it is hardworking, absolutely necessary, yet least appreciated. When we speak about the breakthrough of birth control tablets (there are no “pills” anymore), no one mentions the clever dispensing methods, which require careful packing of the container with the proper active/placebo ratio. The recent bruhaha over the “EpiPen” was totally concerned with its price, not the complex engineering needed to design and build the rapid, accurate, easy-to-operate delivery system.

    I can also assure you that it took as much R&D to develop the plastic bottle and blister packs in which the product is stored for delivery (e.g., 2% TiO2 and the light gets to the drug; 4% and the bottle crumbles over time; 3% and we have the proper light protection with no negative impact on the polymer). An improper additive in a polymer could leach into a parenteral solution or vaccine; an improper polymer could extract a preservative from a similar solution. Thimerosal, for example, was rapidly absorbed by the polypropylene dropper for nose drops, rendering the solution open for breeding bacterial, helping to end its use.

    We tend to accept lab results for things such as blister packaging polymer. It is usually a bi-layer “sandwich,” with the moisture barrier on one side and the lower melting material on the other. We may check the piece of material, but seldom check the actual roll to show that the proper side meets the heated rollers, thence to the case. Oh, the horror of a bad roll.
    In addition, numerous batches of drug are recalled yearly for improper material in containers. We accept the labels without doing a last check before filling. Yes, we really need to examine EVERY part of the supply chain, beyond what we do today.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • canada
    • china
    • quality
    • merck

    Related Columns

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19


    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18

    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18


    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18


    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17

    • Analytical Services
      Quality Risk Management

      Quality Risk Management

      It’s not just for the big guys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 04.03.17

    • Analytical Services | R&D
      Trends in Pharma Analysis

      Trends in Pharma Analysis

      A look at how pharma analysis technology continues to evolve to meet market needs
      Emil W. Ciurczak, DoraMaxx Consulting 03.07.17


    • Analytical Services | Drug Development | Laboratory Testing

      Orphan Drug Development & Production: Turning Lemons into Lemonade

      Forming a “win-win-win” paradigm for large pharma companies, contract service providers and generics
      Emil W. Ciurczak, DoraMaxx Consulting 01.26.17

    • Analytical Services | Bioanalytical Services | Chemistry | Laboratory Testing

      Hyperspectral Imaging

      It’s not just for the Big Boys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 11.09.16

    • Analytical Services | Bioanalytical Services | R&D

      Raman Spectroscopy

      Rapidly becoming the CRO/CMO’s best friend
      Emil W. Ciurczak, DoraMaxx Consulting 10.13.16

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login